223 related articles for article (PubMed ID: 19188159)
1. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
Abe K; Yamamoto N; Domoto T; Bolidong D; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Inatani H; Aoki Y; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Aiba H; Minamoto T; Tsuchiya H
Cancer Sci; 2020 Feb; 111(2):429-440. PubMed ID: 31808966
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Shimasaki T; Ishigaki Y; Nakamura Y; Takata T; Nakaya N; Nakajima H; Sato I; Zhao X; Kitano A; Kawakami K; Tanaka T; Takegami T; Tomosugi N; Minamoto T; Motoo Y
J Gastroenterol; 2012 Mar; 47(3):321-33. PubMed ID: 22041920
[TBL] [Abstract][Full Text] [Related]
5. Detection of active fraction of glycogen synthase kinase 3beta in cancer cells by nonradioisotopic in vitro kinase assay.
Mai W; Miyashita K; Shakoori A; Zhang B; Yu ZW; Takahashi Y; Motoo Y; Kawakami K; Minamoto T
Oncology; 2006; 71(3-4):297-305. PubMed ID: 17652946
[TBL] [Abstract][Full Text] [Related]
6. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
7. GSK3β suppression inhibits MCL1 protein synthesis in human acute myeloid leukemia cells.
Lee YC; Shi YJ; Wang LJ; Chiou JT; Huang CH; Chang LS
J Cell Physiol; 2021 Jan; 236(1):570-586. PubMed ID: 32572959
[TBL] [Abstract][Full Text] [Related]
8. Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression.
Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
HPB (Oxford); 2015 Sep; 17(9):770-6. PubMed ID: 26147011
[TBL] [Abstract][Full Text] [Related]
9. Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.
Madhunapantula SV; Sharma A; Gowda R; Robertson GP
Pigment Cell Melanoma Res; 2013 Nov; 26(6):886-99. PubMed ID: 24034838
[TBL] [Abstract][Full Text] [Related]
10. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.
Carter YM; Kunnimalaiyaan S; Chen H; Gamblin TC; Kunnimalaiyaan M
Cancer Biol Ther; 2014 May; 15(5):510-5. PubMed ID: 24521712
[TBL] [Abstract][Full Text] [Related]
11. Glycogen synthase kinase 3β sustains invasion of glioblastoma via the focal adhesion kinase, Rac1, and c-Jun N-terminal kinase-mediated pathway.
Chikano Y; Domoto T; Furuta T; Sabit H; Kitano-Tamura A; Pyko IV; Takino T; Sai Y; Hayashi Y; Sato H; Miyamoto K; Nakada M; Minamoto T
Mol Cancer Ther; 2015 Feb; 14(2):564-74. PubMed ID: 25504636
[TBL] [Abstract][Full Text] [Related]
12. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells.
Ghosh JC; Altieri DC
Clin Cancer Res; 2005 Jun; 11(12):4580-8. PubMed ID: 15958644
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk between glycogen synthase kinase 3β (GSK3β) and p38MAPK regulates myocyte enhancer factor 2 (MEF2) activity in skeletal and cardiac muscle.
Dionyssiou MG; Nowacki NB; Hashemi S; Zhao J; Kerr A; Tsushima RG; McDermott JC
J Mol Cell Cardiol; 2013 Jan; 54():35-44. PubMed ID: 23137781
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells.
Yoshino Y; Ishioka C
Sci Rep; 2015 Aug; 5():13249. PubMed ID: 26292722
[TBL] [Abstract][Full Text] [Related]
15. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta.
Miyashita K; Nakada M; Shakoori A; Ishigaki Y; Shimasaki T; Motoo Y; Kawakami K; Minamoto T
Anticancer Agents Med Chem; 2009 Dec; 9(10):1114-22. PubMed ID: 19925395
[TBL] [Abstract][Full Text] [Related]
16. Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase.
Mai W; Kawakami K; Shakoori A; Kyo S; Miyashita K; Yokoi K; Jin M; Shimasaki T; Motoo Y; Minamoto T
Clin Cancer Res; 2009 Nov; 15(22):6810-9. PubMed ID: 19903789
[TBL] [Abstract][Full Text] [Related]
17. Nuclear GSK3β induces DNA double-strand break repair by phosphorylating 53BP1 in glioblastoma.
Yang Y; Lei T; Du S; Tong R; Wang H; Yang J; Huang J; Sun M; Wang Y; Dong Z
Int J Oncol; 2018 Mar; 52(3):709-720. PubMed ID: 29328365
[TBL] [Abstract][Full Text] [Related]
18. CCR7-dependent stimulation of survival in dendritic cells involves inhibition of GSK3beta.
Escribano C; Delgado-Martín C; Rodríguez-Fernández JL
J Immunol; 2009 Nov; 183(10):6282-95. PubMed ID: 19841191
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3beta (GSK-3beta) inhibitors AR-A014418 and B6B3O prevent human immunodeficiency virus-mediated neurotoxicity in primary human neurons.
Nguyen TB; Lucero GR; Chana G; Hult BJ; Tatro ET; Masliah E; Grant I; Achim CL; Everall IP;
J Neurovirol; 2009 Sep; 15(5-6):434-8. PubMed ID: 19688630
[TBL] [Abstract][Full Text] [Related]
20. Potential Role of Glycogen Synthase Kinase-3β in Regulation of Myocardin Activity in Human Vascular Smooth Muscle Cells.
Zhou YX; Shi Z; Singh P; Yin H; Yu YN; Li L; Walsh MP; Gui Y; Zheng XL
J Cell Physiol; 2016 Feb; 231(2):393-402. PubMed ID: 26129946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
